Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Moodys
McKesson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Acetazolamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000115 ↗ Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema Completed National Eye Institute (NEI) Phase 2 1990-12-01 To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00004802 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed Ohio State University Phase 3 1992-06-01 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed National Center for Research Resources (NCRR) Phase 3 1992-06-01 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00108602 ↗ Sleep Apnea: Mechanism and Cerebrovascular Consequences Withdrawn US Department of Veterans Affairs N/A 2007-05-01 This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.
NCT00108602 ↗ Sleep Apnea: Mechanism and Cerebrovascular Consequences Withdrawn VA Office of Research and Development N/A 2007-05-01 This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.
NCT00120731 ↗ Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones Withdrawn Children's Mercy Hospital Kansas City N/A 2005-07-01 High amounts of calcium in the urine (hypercalciuria) can cause development of kidney stones in children. Treatment for these children includes plenty of fluids, a low-salt diet and medications such as potassium citrate. A major advantage of potassium citrate, as compared to hydrochlorothiazide, is its lack of side effects. One problem the researchers and others have observed is that some children continue to form kidney stones despite correction of hypercalciuria with potassium citrate. One possible explanation is that in some individuals potassium citrate therapy results in an excessive elevation of urine pH, a situation that may predispose to calcium phosphate stone formation. In this study, the researchers will study the effects of potassium citrate on urine chemistries and acid-base balance in three groups of children aged 5-17 years: - children who are hypercalciuric stone formers; - healthy children without a history of hypercalciuria or kidney stones. Particular attention will be paid to try to identify those who develop a very high urine pH (>8) and the factors leading to this metabolic reaction. The researchers will try to learn whether it is the child's characteristics, the disease manifestations, the dose of the drug, or a combination of the above which may be the cause of the development of very alkaline urine. Based on the results, the researchers hope to be able to better "tailor" the individual treatment for each child with kidney stones.
NCT00222534 ↗ Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis Completed University of Oslo School of Pharmacy Phase 4 2002-01-01 Respiratory failure is a common consequence of chronic obstructive pulmonary disease (COPD). A concurrent metabolic alkalosis may worsen the respiratory failure, as a higher pH in blood (and thus in cerebrospinal fluid) results in a weaker respiratory drive. Use of diuretics is the most common cause of metabolic alkalosis. When a patient with an acute exacerbation of a respiratory failure is also alkalotic, there are (at least theoretical) reasons to lower the pH in order to increase the respiratory drive. Among other alternatives, the drug acetazolamide can be used for this purpose. In some hospitals there is a tradition for the use of acetazolamide on this indication, but any evidence for the effect of such a treatment is rather weak. Thus, the aim of this trial is to evaluate the effect of acetazolamide as an adjuvant treatment for hospitalized patients with acute exacerbation of respiratory failure in combination with metabolic alkalosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acetazolamide

Condition Name

Condition Name for Acetazolamide
Intervention Trials
Altitude Hypoxia 8
Chronic Obstructive Pulmonary Disease 8
Acute Mountain Sickness 8
Obstructive Sleep Apnea 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acetazolamide
Intervention Trials
Altitude Sickness 27
Sleep Apnea Syndromes 14
Hypoxia 13
Pulmonary Disease, Chronic Obstructive 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acetazolamide

Trials by Country

Trials by Country for Acetazolamide
Location Trials
United States 99
Kyrgyzstan 18
Canada 6
Israel 6
Belgium 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acetazolamide
Location Trials
Massachusetts 9
California 9
New York 6
Florida 5
Pennsylvania 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acetazolamide

Clinical Trial Phase

Clinical Trial Phase for Acetazolamide
Clinical Trial Phase Trials
Phase 4 43
Phase 3 14
Phase 2/Phase 3 6
[disabled in preview] 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acetazolamide
Clinical Trial Phase Trials
Completed 64
Recruiting 17
Unknown status 12
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acetazolamide

Sponsor Name

Sponsor Name for Acetazolamide
Sponsor Trials
University of Zurich 23
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov 16
National Eye Institute (NEI) 5
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acetazolamide
Sponsor Trials
Other 181
NIH 13
U.S. Fed 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.